Husain M, Bain SC, Jeppesen OK, et al. - Researchers performed a post hoc analysis to compare the utility of semaglutide with comparators on major adverse cardiovascular events (MACE) and hospitalization for heart failure (HF) in the SUSTAIN (subcutaneous semaglutide) and PIONEER (oral semaglutide) trials across subgroups of varying cardiovascular risk. They investigated MACE in individuals with and without developed cardiovascular disease and/or chronic kidney disease, prior myocardial infarction or stroke, and prior HF. They further analyzed MACE among participants in the SUSTAIN and PIONEER trials with respect to glycemic utility. The HR for impact of semaglutide vs comparators on MACE was 0.85 in combined glycemic utility trials. Overall, in SUSTAIN and PIONEER combined, glucagon-like peptide-1 analogue semaglutide demonstrated logical impacts on MACE vs comparators across varying cardiovascular risk. There was no impact of semaglutide on MACE in individuals with prior HF.